Researchers have presented comprehensive multi-omic profiles to identify genes, non-coding RNAs, proteins, and plasma metabolites involved in NAFLD-to-NASH progression.
List view / Grid view
Japanese researchers showed for the first time processes that are crucial targets for treating liver cancer are enhanced by saturated fatty acid diets.
Elevated lipoprotein(a), or Lp(a), is a major risk factor for cardiovascular disease that affects one in five people worldwide, but currently lacks approved therapies. Here, Dr Giles Campion, EVP, Head of R&D and Chief Medical Officer of Silence Therapeutics, describes the company’s approach to developing an investigational siRNA therapy designed…
Researchers have developed a computational DNA droplet with the ability to recognise specific combinations of chemically synthesised microRNAs that act as biomarkers of tumours.
According to researchers, an interaction between host microRNA and SARS-CoV-2 could be responsible for the range of disease severities.
A team has found that a mutation in the ATAXIN-1 gene causes spinocerebellar ataxia type 1 (SCA1), presenting a drug target for the condition.
Drug Target Review rounds up some of the latest news in COVID-19 vaccine candidate R&D.
Researchers have revealed that the microRNA miR-218-5p promoted hair growth in mice, so is a promising drug target for hair loss.
The TAp63 tumour suppressor protein, two micro RNAs (miRNAs) and the AURKA gene can all suppress cutaneous squamous cell carcinoma (cuSCC) development, find researchers.
A new study has shown that mutations in mitochondrial DNA induced by cell reprogramming may trigger an immune response.
Newly developed HDO-antimiR could lead to new ways to treat diseases which are caused by malfunctioning miRNAs.
An engineered virus kills cancer cells more effectively than another virus currently used in treatments, according to Hokkaido University researchers...
Researchers have pinpointed a single molecule - microRNA-31 (miR-31) - the levels of which predict whether a patient has subtype 1 or subtype 2 of Crohn's disease...
This webinar, held on 28 June 2018, illustrated the optimisation of hits derived from a target-agnostic phenotypic screen, using a strategy based on combining bioactivity profiling and reference compound characterisation. Keynote speaker Arsenio Nueda, Head of Molecular Biology at Almirall, responded as follows to questions posed during the webinar.